Medicines for the People Act

This bill would create a new National Institute for Biomedical Research and Development within the National Institutes of Health. The institute would research, develop, test, and seek federal approval for drugs, medical devices, and biological products, and the federal government would own the resulting patents and trade secrets. Approved products would be made by the government and sold at cost where practicable; otherwise patents could be licensed, free to public and nonprofit entities and with cost-plus pricing terms for for-profit companies. A 15-member governing board appointed by the Secretary of Health and Human Services would set priorities, with limits on members tied to the for-profit sector or drug-company lobbying. The bill authorizes $90 billion for fiscal year 2027.

Full text and official record on Congress.gov

Sponsors

• Rashida Tlaib Democrat sponsor
• 4 cosponsors